ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2855

Expanding the Phenotype: New Variant in the IL1RN-Gene Associated with Late Onset and Atypical Presentation of Dira

Jasmin B. Kuemmerle-Deschner1, Konstanze Hoertnagel2, Susanne Schlipf3, Sandra Hansmann4, Toni Hospach5, Ilias Tsiflikas6, Xiao Liu7, Susanne Benseler8 and Alexander Weber7, 1Department of Pediatrics, Division of Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, 2Praxis für Humangenetik Tübingen,Tuebingen, Germany, Tuebingen, Germany, 3Kinderarztpraxis Dr. Lakner, Schwäbisch Gmünd, Germany, Schwäbisch Gmünd, Germany, 4Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, Tuebingen, Germany, 5Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, 6Division of Pediatric Radiology, Department of Radiology, University Hospital Tuebingen, Germany, Tuebingen, Germany, 7Department of Immunology, University of Tübingen, Tübingen, Germany, Tuebingen, Germany, 8Rheumatology, Department of Paediatrics, Alberta Children's Hospital, University of Calgary, Alberta, Canada, Calgary, AB, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Autoinflammatory Disease, Biologic agents, genetic disorders and phenotypes, IL-1

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: 5T105 ACR Abstract: Innate Immunity (2850–2855)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Deficiency of the Interleukin-1 receptor antagonist (DIRA) is an autoinflammatory disease of infancy characterized by severe systemic inflammation with bone and skin involvement. This is a report of a novel variant in the IL1RN-gene associated with late onset and atypical phenotype of DIRA.

Methods: A 3 year-old Caucasian boy presented with recurrent monthly episodes of fever and fatigue, associated with lymphadenopathy, pericarditis, pleuritis, pancreatitis, and arthritis involving sacroiliac, hip, knee and ankle joints in the absence of skin involvement. Symptoms had started at age one and progressed over time to life-threatening episodes requiring intensive care. Throughout, ESR, CRP, SAA, S100A8/9, leukocytes, and platelets were highly elevated. Treatment with colchicine and steroids improved symptoms; however, did not prevent flares. Genetic testing did not identify known pathogenic variants of immune deficiencies and AIDs including DITRA.

Results: Whole exome sequencing detected a novel homozygous stop variant c.62C>G; p.Ser21* in the ILRN gene (NM_173842.2). Mother, father and brother were heterozygous for the same variant. In addition, three variants of unknown significance were identified in the patient’s PCGF5, CPA1 and SPTA1 genes. Functional studies revealed marginally low secretion of IL-1RA from unstimulated leucocytes and after stimulation with IL-1β and LPS, confirming the disease-causing nature of the variant. IL-1 inhibition with anakinra at 2 mg/kg/d was started resulting in complete resolution of clinical symptoms, inflammatory markers and signs of inflammation on MRI. Intolerance to daily sc injections prompted a switch to canakinumab at 4 mg/kg/4 weeks. However, canakinumab did not prevent significant disease flares including new bone inflammation. Re-start of anakinra resulted in recapture of disease control.

Conclusion: This is the first report of the novel c.62C>G; p.Ser21* variant in the IL1RN-gene resulting in late onset DIRA with prominent systemic and bone/joint inflammation. DIRA should be considered in older children even in the absence of skin disease.


Disclosure: J. B. Kuemmerle-Deschner, Novartis, 2,Novartis, SOBI, 5; K. Hoertnagel, None; S. Schlipf, None; S. Hansmann, None; T. Hospach, None; I. Tsiflikas, None; X. Liu, None; S. Benseler, None; A. Weber, None.

To cite this abstract in AMA style:

Kuemmerle-Deschner JB, Hoertnagel K, Schlipf S, Hansmann S, Hospach T, Tsiflikas I, Liu X, Benseler S, Weber A. Expanding the Phenotype: New Variant in the IL1RN-Gene Associated with Late Onset and Atypical Presentation of Dira [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/expanding-the-phenotype-new-variant-in-the-il1rn-gene-associated-with-late-onset-and-atypical-presentation-of-dira/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expanding-the-phenotype-new-variant-in-the-il1rn-gene-associated-with-late-onset-and-atypical-presentation-of-dira/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology